INBX
Inhibrx Biosciences, Inc.
$97.58
+2.64 (+2.78%)
At close · Jul 2
Market Cap
$1.43B
Shares
14,671,186
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$97.58
Open$96.40
Day$91.37–97.59
52W$14.95–155.29
Avg vol 30d313K
Short int3.3M · 22.5% float · 10.3d
Short vol57%
Last earningsMay 14, 2026
DataMay 2024–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+25% above
−
Price vs 50-day avg
−9% below
◦
RSI (14)
52 · neutral
+
MACD trend
positive
◦
52-week position
59% · mid-range
Sentiment · smart money
Neutral
◦
Trend (MA cross)
50d $107 › 200d $78 — 50d above 200d
+
Institutional flow
2 of 137 funds reported for Jun 30 · net +5 sh shares · +1 new
◦
Insider flow
No net insider activity over 90 days
−
Short interest
22.49% of float · ▲ +3.8% MoM · 10.3 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
137 holders — mid 2-yr range
Fundamentals
Fair
+
Revenue growth
+550% Y/Y
−
EPS growth
−108% Y/Y
−
Free cash flow
$-129.8M
+
Balance sheet
net cash $124.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 14, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+25% above
Bullish
Price vs 50-day avg
−9% below
Bearish
RSI (14)
52 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
59% · mid-range
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $107 › 200d $78 — 50d above 200d
Institutional flow
Accumulating
2 of 137 funds reported for Jun 30 · net +5 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
22.49% of float · ▲ +3.8% MoM · 10.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
137 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $15
Now $98 · 59%
52-wk high $155
vs 200-day avg +25%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INBX
this stock
Inhibrx Biosciences, Inc.
|
$1.43B | +23.5% | -88.9% | — | 22.5% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INBX | +2.4% | +2.5% | +29.8% | +3.0% | +23.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +1.0% | +3.7% | +21.7% | +3.3% | +14.3% |